1,369 results match your criteria Hematological Oncology[Journal]


Mina53 regulates the differentiation and proliferation of leukemia cells.

Hematol Oncol 2019 Apr 16. Epub 2019 Apr 16.

College of Life Sciences, Zhejiang University, Hangzhou, China.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/hon.2621DOI Listing

Impact of 2016-WHO diagnosis of early and overt primary myelofibrosis on presentation and outcome of 232 patients treated with ruxolitinib.

Hematol Oncol 2019 Apr 15. Epub 2019 Apr 15.

Division of Cellular Biotechnologies and Hematology, University Sapienza, Roma.

2016-WHO criteria identified early-Primary Myelofibrosis as an individual entity with milder clinical features and better outcome compared to overt-PMF. Here, we compared early and overt-PMF patients treated with ruxolitinib in terms of baseline clinical/laboratory characteristics, response and toxicity to treatment. We observed that early-PMF patients achieve better and more stable spleen and symptoms responses, with significantly lower rates of haematological toxicities. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/hon.2619DOI Listing
April 2019
2 Reads

A Multi-Center Retrospective Comparison of Induction Chemoimmunotherapy Regimens on Outcomes in Transplant-eligible Patients with Previously Untreated Mantle Cell Lymphoma.

Hematol Oncol 2019 Apr 15. Epub 2019 Apr 15.

Department of Haematology, Sir Charles Gairdner Hospital, Nedlands, Western Australia, Australia.

Mantle cell lymphoma (MCL) is an uncommon and typically aggressive form of lymphoma. Although often initially chemosensitive, relapse is common. Several induction and conditioning regimens are used in transplant eligible patients and the optimal approach remains unknown. Read More

View Article

Download full-text PDF

Source
https://onlinelibrary.wiley.com/doi/abs/10.1002/hon.2618
Publisher Site
http://dx.doi.org/10.1002/hon.2618DOI Listing
April 2019
2 Reads

Identification of a novel tRNA-derived RNA fragment exhibiting high prognostic potential in chronic lymphocytic leukemia.

Hematol Oncol 2019 Apr 4. Epub 2019 Apr 4.

Department of Biochemistry and Molecular Biology, National and Kapodistrian University of Athens, GR, Athens, Greece.

tRNA-derived fragments (tRFs) are 16-28 nucleotide fragments, which occur by specific cleavage of tRNA molecules. i-tRF-GlyGCC is an internal tRF, originating from the tRNAs bearing the Glycine anticodon "GCC". Other tRFs generated from tRNA have proved to be associated with various cancer types. Read More

View Article

Download full-text PDF

Source
https://onlinelibrary.wiley.com/doi/abs/10.1002/hon.2616
Publisher Site
http://dx.doi.org/10.1002/hon.2616DOI Listing
April 2019
2 Reads

Induction therapy in acute myeloid leukemia: is it time to put aside standard 3 + 7 ?

Hematol Oncol 2019 Apr 2. Epub 2019 Apr 2.

Division of Hematology, Cardarelli Hospital, Naples, Italy.

For more than 30 years after its introduction, the combination of an anthracycline, usually daunorubicin, given for 3 days with continuous infusion of cytarabine for 7 days (3+7) has been the standard induction regimen for patients with acute myeloid leukemia (AML). In the last decade, there has been a progressive understanding of the molecular pathogenesis of the disease which has led to discovery of potential therapeutic targets, resulting in selective treatment approaches aimed at rational and personalized treatment strategies. In the last 2 years, different new agents for AML have become widely available for newly diagnosed or relapsing/refractory patients and others are object of clinical investigation. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/hon.2615DOI Listing
April 2019
7 Reads

Front-line treatment of Diffuse large B-cell lymphoma: beyond R-CHOP.

Hematol Oncol 2019 Apr 2. Epub 2019 Apr 2.

Department of Hematology & CBMT, Ospedale di Bolzano, Bolzano, Italy.

Although the majority of patients with diffuse large B-cell lymphoma (DLBCL) can be cured with the standard immunochemotherapy R-CHOP, one-third of them relapses with a dismal outcome in most cases. In the recent years remarkable advances have been achieved based on the discovery of molecular genetics in DLBCL. In addition to the major cell-of-origin designations of germinal center B-cell and activated B-cell subtypes, next-generation sequencing has unveiled the remarkable complexity of DLBCL and identified potential molecular targets for tailored therapies. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/hon.2613DOI Listing
April 2019
4 Reads
3.084 Impact Factor

Metabolic tumour volume and response to therapy in diffuse large B cell lymphoma.

Hematol Oncol 2019 Apr 1. Epub 2019 Apr 1.

Department of Medicine and Surgery, Unit of Internal Medicine, University of Insubria, Varese.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/hon.2612DOI Listing
April 2019
3 Reads

Relative dose intensity of R-CHOP therapy and patient outcomes in advanced follicular lymphoma.

Hematol Oncol 2019 Apr 1. Epub 2019 Apr 1.

Department of Medical Oncology, Tokyo Metropolitan Cancer and Infectious Diseases Center Komagome Hospital, Tokyo, Japan.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/hon.2614DOI Listing
April 2019
2 Reads

RNA-Seq Analyses Demonstrate EVI-1-induced Morbid Hematopoiesis and Developmental Abnormality in Zebrafish were Related with MAPK Pathway.

Hematol Oncol 2019 Mar 28. Epub 2019 Mar 28.

Department of Hematology, Ren Ji Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai, China.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/hon.2609DOI Listing

Cardiovascular mortality among patients with non-Hodgkin lymphoma: Differences according to lymphoma subtype.

Hematol Oncol 2019 Mar 27. Epub 2019 Mar 27.

University of Connecticut/Hartford Hospital Evidence-based Practice Center, Hartford, Connecticut, United States of America.

Survival rates of patients with non-Hodgkin lymphoma (NHL) have improved over the last decade. However, cardiotoxicities remain important adverse consequences of treatment with chemotherapy and radiation, although the burden of cardiovascular mortality (CVM) in such patients remains unknown. We conducted a retrospective cohort study of patients greater than or equal to 20 years of age diagnosed with diffuse large B-cell lymphoma (DLBCL), follicular lymphoma (FL), and chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) between 2000 and 2013 using data extracted from the United States Surveillance, Epidemiology, and End Results (SEER) database. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/hon.2607DOI Listing
March 2019
5 Reads

Arterial occlusive events in chronic myeloid leukemia patients treated with ponatinib in the real-life practice are predicted by the Systematic Coronary Risk Evaluation (SCORE) chart.

Hematol Oncol 2019 Mar 20. Epub 2019 Mar 20.

Hematology, Department of Cellular Biotechnologies and Hematology, Sapienza University, Rome, Italy.

Arterial occlusive events (AOEs) represent emerging complications in chronic myeloid leukemia (CML) patients treated with ponatinib. We identified 85 consecutive CML adult patients who were treated with ponatinib in 17 Italian centers. Patients were stratified according to the Systematic Coronary Risk Evaluation (SCORE) assessment, based on sex, age, smoking habits, systolic blood pressure, and total cholesterol levels. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/hon.2606DOI Listing
March 2019
1 Read
3.084 Impact Factor

A case report of systemic mastocytosis associated with multiple hematologic non-mast cell lineage diseases.

Hematol Oncol 2019 Mar 8. Epub 2019 Mar 8.

Hematology Unit, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milan, Italy.

Systemic mastocytosis (SM) is a hematological malignancy characterized by extracutaneous infiltration by atypical mast cells. Together with indolent SM, aggressive SM, and mast cell leukemia, the World Health Organization (WHO) recognizes another major disease subgroup: SM with an associated hematological neoplasm, which is characterized by the presence of a concurrent neoplasm, more commonly, a chronic myelomonocytic leukemia. While KIT D816V is commonly regarded as the driver mutation, the clinical presentation of SM is extremely varied. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/hon.2605DOI Listing
March 2019
3 Reads

Critical evaluation of current molecular MRD strategies including NGS for the management of AML patients with multiple mutations.

Hematol Oncol 2019 Mar 6. Epub 2019 Mar 6.

University Department of Hematology and Central Hematology Laboratory, Inselspital, Bern University Hospital, Bern, Switzerland.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/hon.2603DOI Listing
March 2019
1 Read

Transformed follicular lymphoma in the rituximab era: A report from the Spanish Lymphoma Oncology Group.

Hematol Oncol 2019 Mar 6. Epub 2019 Mar 6.

Medical Oncology Department, Hospital Universitario Puerta de Hierro-Majadahonda, Madrid, Spain.

Follicular lymphoma (FL) is the second most common non-Hodgkin lymphoma (NHL) subtype. The histological transformation (HT) of FL is an event considered frequent in the natural history of this tumor. We studied the transformation rates, predictive factors, and treatment characteristics that may impact in the survival of patients with FL and HT. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/hon.2601DOI Listing
March 2019
1 Read

The Italian-Canine Cancer Biobank: Our 10-year challenge.

Hematol Oncol 2019 Mar 5. Epub 2019 Mar 5.

Dipartimento di Scienze Veterinarie, Università degli Studi di Torino, Torino, Italy.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/hon.2602DOI Listing

Dual-tracer PET/CT scan after injection of combined [ F]NaF and [ F]FDG outperforms MRI in the detection of myeloma lesions.

Hematol Oncol 2019 Feb 28. Epub 2019 Feb 28.

Department of Clinical Hematology, CHU of Liège, Liège, Belgium.

The detection rates of whole-body combined [ F]NaF/[ F]FDG positron emission tomography combined with computed tomography (PET/CT), CT alone, whole-body magnetic resonance imaging (WB-MRI), and X-ray were prospectively studied in patients with treatment-requiring plasma cell disorders The detection rates of imaging techniques were compared, and focal lesions were classified according to their anatomic location. Twenty-six out of 30 initially included patients were assessable. The number of focal lesions detected in newly diagnosed patients (n = 13) and in relapsed patients (n = 13) were 296 and 234, respectively. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/hon.2600DOI Listing
February 2019

Refractoriness to immunochemotherapy in follicular lymphoma: Predictive factors and outcome.

Authors:

Hematol Oncol 2019 Feb;37(1):114

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/hon.2526DOI Listing
February 2019
1 Read

Low-dose fludarabine and cyclophosphamide combined with standard dose rituximab (LD-FCR) is an effective and safe regimen for elderly untreated patients with chronic lymphocytic leukemia: The Israeli CLL study group experience.

Hematol Oncol 2019 Feb 12. Epub 2019 Feb 12.

Department of Hematology, Hadassah University Hospital and Hebrew University Medical School, Jerusalem, Israel.

Chronic lymphocytic leukemia (CLL) is a disease of elderly patients. The fludarabine, cyclophosphamide, and rituximab (FCR) regimen is considered the treatment of choice for young fit patients with CLL; however, this combination is toxic for older patients. At the time this study was first planned and initiated, there was no standard chemo-immunotherapy regimen regarded as standard therapy for the less fit elderly patient with CLL. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/hon.2580DOI Listing
February 2019
2 Reads

Treatment of diffuse large B-cell lymphoma with and without anthracyclines and rituximab in patients older than 60 years: 10-year results at a Latin American center.

Hematol Oncol 2019 Feb 11. Epub 2019 Feb 11.

Department of Hematology, Internal Medicine Division, Dr. José E. González University Hospital of the School of Medicine of the Universidad Autónoma de Nuevo León, Monterrey, Mexico.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/hon.2579DOI Listing
February 2019
3 Reads

Exercise prescription and tailored physical activity intervention in onco-hematology inpatients, a personalized bedside approach to improve clinical best practice.

Hematol Oncol 2019 Feb 8. Epub 2019 Feb 8.

Sport and Exercise Medicine Division, Department of Medicine, University of Padova, Padova, Italy.

Therapy of hematological malignancies lasts for long periods implicating various complications. The chemotherapy induces fatigue and forces bed rest. These features strongly contribute to a general impairment of the physical efficiency. Read More

View Article

Download full-text PDF

Source
http://doi.wiley.com/10.1002/hon.2576
Publisher Site
http://dx.doi.org/10.1002/hon.2576DOI Listing
February 2019
9 Reads

Differential expression of estrogen receptor-α on follicular dendritic cells from patients with grade 1-2 and grade 3 follicular lymphoma.

Hematol Oncol 2019 Feb 8. Epub 2019 Feb 8.

Department of Pathological Diagnostics, Yamagata University Faculty of Medicine, Yamagata, Japan.

Hormone therapy has been used for patients with estrogen receptor alpha (ERα)-positive breast cancers. Recently, some studies reported the expression of ERα on neoplastic cells from B-cell lymphomas. However, there has been only one report of ERα expression on the follicular dendritic cells (FDCs) that structurally and functionally support the microenvironment of follicular lymphomas (FLs). Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/hon.2577DOI Listing
February 2019
2 Reads

FDG PET/CT as a diagnostic and prognostic tool for the evaluation of marginal zone lymphoma.

Hematol Oncol 2019 Feb 8. Epub 2019 Feb 8.

Sackler Faculty of Medicine, Tel-Aviv University, Tel-Aviv, Israel.

We evaluated the role of 18-fluoro-2-deoxy-d-glucose positron emission tomography ( FDG-PET) with computed tomography (CT) (PET/CT) as a diagnostic and prognostic tool in newly diagnosed marginal zone lymphoma (MZL) patients. This is a retrospective cohort study of patients with newly diagnosed MZL, treated with immunotherapy, chemotherapy regimens, surgery, or Helicobacter pylori eradication between 2008 and 2016 in a single tertiary center. Only patients who had a pretreatment PET/CT (P-PET/CT) were included. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/hon.2578DOI Listing
February 2019
5 Reads

Lymphomas associated with chronic hepatitis C virus infection: A prospective multicenter cohort study from the Rete Ematologica Lombarda (REL) clinical network.

Hematol Oncol 2019 Feb 6. Epub 2019 Feb 6.

Division of Hematology, Fondazione IRCCS Policlinico San Matteo, Pavia, Italy.

Chronic hepatitis C virus (HCV) infection is related with an increased risk of non-Hodgkin lymphomas (NHL). In indolent subtypes, regression of NHL was reported after HCV eradication with antiviral therapy (AT). In 2008 in Lombardy, a region of Northern Italy, the "Rete Ematologica Lombarda" (REL, Hematology Network of Lombardy-Lymphoma Workgroup) started a prospective multicenter observational cohort study on NHL associated with HCV infection, named "Registro Lombardo dei Linfomi HCV-positivi" ("Lombardy Registry of HCV-associated non-Hodgkin lymphomas"). Read More

View Article

Download full-text PDF

Source
https://onlinelibrary.wiley.com/doi/abs/10.1002/hon.2575
Publisher Site
http://dx.doi.org/10.1002/hon.2575DOI Listing
February 2019
13 Reads

A case report of the long treatment experience of a Sézary syndrome responder patient: 16 years through all the systemic and innovative therapies.

Hematol Oncol 2019 Jan 13. Epub 2019 Jan 13.

Institute of Hematology "L. e A. Seràgnoli,", University of Bologna, Bologna, Italy.

Existing therapies for Sézary syndrome (SS) are limited in efficacy and in disease control, and patients have very poor prognosis. Here, we report a case report of a patient who has a 16-year history of SS and related treatments (both standard and experimental). In particular, two drugs, one conventional (gemcitabine) and one experimental (mogamulizumab), were able to induce long lasting response. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/hon.2573DOI Listing
January 2019
1 Read

Treatment of diffuse large B-cell lymphoma in elderly patients: Replacing doxorubicin with either epirubicin or etoposide (VP-16).

Hematol Oncol 2018 Dec 27. Epub 2018 Dec 27.

Department of Oncology and Radiotherapy, Oulu University Hospital, Oulu, Finland.

View Article

Download full-text PDF

Source
http://doi.wiley.com/10.1002/hon.2572
Publisher Site
http://dx.doi.org/10.1002/hon.2572DOI Listing
December 2018
14 Reads

Exportin-1 E571K mutation is a common finding in patients with classical Hodgkin lymphoma.

Hematol Oncol 2018 Dec 13. Epub 2018 Dec 13.

Centro de Investigación del Cáncer de Salamanca; Servicio de Hematología, Hospital Universitario de Salamanca; Instituto de Investigación Biomédica de Salamanca (IBSAL), Salamanca, Spain.

View Article

Download full-text PDF

Source
https://onlinelibrary.wiley.com/doi/abs/10.1002/hon.2570
Publisher Site
http://dx.doi.org/10.1002/hon.2570DOI Listing
December 2018
25 Reads

Cutaneous manifestations of hematologic malignancies the experience of an Italian dermatology department.

Hematol Oncol 2018 Nov 28. Epub 2018 Nov 28.

Di.S.Sal. Section of Dermatology, University of Genoa, San Martino Polyclinic Hospital, Genoa, Italy.

In recent years, dermatologic manifestations in oncohematologic patients have become more common. The aim of our study was to determine the incidence and heterogeneity of skin manifestations in patients followed at our Hematology Department. This observational monocentrical study was conducted on 60 patients. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/hon.2569DOI Listing
November 2018
15 Reads

The acceleration of CAR-T therapy in non-Hodgkin lymphoma.

Hematol Oncol 2018 Nov 14. Epub 2018 Nov 14.

Seattle Cancer Care Alliance, University of Washington/Fred Hutchinson Cancer Research Center Seattle, Seattle, Washington, USA.

Recent advances in diffuse large B-cell lymphomas have included both identification of high-risk subtypes characterized by multiply relapsed and/or refractory disease as well as novel treatment in the form of cellular therapy. Chimeric antigen receptor (CAR)-T cell therapy is a recently developed approach to address the poor outcomes in this patient population. The CAR-T cell construct has evolved although several iterations as it transitioned from the lab to the clinic. Read More

View Article

Download full-text PDF

Source
http://doi.wiley.com/10.1002/hon.2568
Publisher Site
http://dx.doi.org/10.1002/hon.2568DOI Listing
November 2018
24 Reads

MicroRNA expression profiles discriminate childhood T- from B-acute lymphoblastic leukemia.

Hematol Oncol 2019 Feb 27;37(1):103-112. Epub 2018 Nov 27.

Laboratory of Immunogenetics, Department of Immunology, Aggeu Magalhães Institute, Recife, Brazil.

MicroRNAs (miRNAs) play a critical role on biological and cellular processes; the search for functional markers may be of importance for differential diagnosis, prognosis, and development of new therapeutic regimens. In this context, we evaluated the bone marrow miRNA profile of Brazilian children exhibiting T- or B-cell acute lymphoblastic leukemia (T-ALL or B-ALL), using massive parallel sequencing, using the HiSeq 2500 platform (Illumina). The differential expression analysis was conducted considering a leave-one-out approach and FDR ≤ 0. Read More

View Article

Download full-text PDF

Source
http://doi.wiley.com/10.1002/hon.2567
Publisher Site
http://dx.doi.org/10.1002/hon.2567DOI Listing
February 2019
11 Reads

Induction chemotherapy followed by allogeneic HCT versus upfront allogeneic HCT for advanced myelodysplastic syndrome: A propensity score matched analysis.

Hematol Oncol 2019 Feb 19;37(1):85-95. Epub 2018 Nov 19.

Department of Hematology, Kanazawa University Hospital, Kanazawa, Japan.

To reduce post-transplant relapse, acute myeloid leukemia (AML) type remission induction chemotherapy has been attempted to reduce disease burden before allogeneic hematopoietic cell transplantation (HCT) in patients with advanced myelodysplastic syndrome (MDS). However, the efficacy of induction chemotherapy before HCT is unclear. We retrospectively analyzed the Japanese registration data of 605 adult patients, who had received allogeneic HCT for advanced MDS between 2001 and 2016, to compare the post-transplant relapse between patients who received induction chemotherapy followed by allogeneic HCT and those who received upfront HCT. Read More

View Article

Download full-text PDF

Source
http://doi.wiley.com/10.1002/hon.2566
Publisher Site
http://dx.doi.org/10.1002/hon.2566DOI Listing
February 2019
5 Reads

Managing the cervical spine in multiple myeloma patients.

Hematol Oncol 2018 Oct 17. Epub 2018 Oct 17.

Myeloma Spine Service, Department of Spinal Surgery, Royal National Orthopaedic Hospital, Stanmore, Middlesex, UK.

Discuss the relevant literature on surgical and nonsurgical treatments for multiple myeloma (MM) and their complementary effects on overall treatment. Existing surgical algorithms designed for neoplasia of the spine may not suit the management of spinal myeloma. Less than a fifth of metastatic, including myelomatous lesions, occur in the cervical spine but have a poorer prognosis and surgery in this area carries a higher morbidity. Read More

View Article

Download full-text PDF

Source
http://doi.wiley.com/10.1002/hon.2564
Publisher Site
http://dx.doi.org/10.1002/hon.2564DOI Listing
October 2018
14 Reads

Prognostic role of baseline F-FDG PET/CT parameters in MALT lymphoma.

Hematol Oncol 2019 Feb 8;37(1):39-46. Epub 2018 Nov 8.

Department of Nuclear Medicine, University of Brescia and Spedali Civili di Brescia, Brescia, Italy.

Mucosa-associated lymphoid tissue (MALT) lymphoma is an indolent lymphoma with good prognosis and variable fluorine-18 fluorodeoxyglucose ( F-FDG) avidity. Many possible prognostic factors have been investigated with controversial results, but the possible prognostic role of F-FDG positron emission tomography/computed tomography (PET/CT) remains unclear. Our aim was to evaluate the prognostic impact of qualitative and semiquantitative baseline PET/CT parameters on outcome of MALT lymphoma. Read More

View Article

Download full-text PDF

Source
http://doi.wiley.com/10.1002/hon.2563
Publisher Site
http://dx.doi.org/10.1002/hon.2563DOI Listing
February 2019
23 Reads

Lymphomagenic properties of a HIV p17 variant derived from a splenic marginal zone lymphoma occurred in a HIV-infected patient.

Hematol Oncol 2018 Sep 27. Epub 2018 Sep 27.

Immunopathology and Biomarker Unit, Department of Translational Research, Centro di Riferimento Oncologico di Aviano, IRCCS, Aviano, Italy.

Despite antiretroviral therapy, HIV+ individuals still have increased risk to develop lymphomas, including marginal zone lymphomas, suggesting that factors other than HIV-related immunosuppression are probably acting as lymphomagenic factors in the HIV setting. The possible pathogenic involvement of HIV p17 protein variants was investigated in a particularly informative case of HIV-related splenic marginal zone lymphoma, which was negative for oncogenic virus infections, thus allowing us to assess the possible direct contribution of these HIV-encoded proteins to lymphomagenesis. The presence of p17 protein was analyzed by immunohistochemistry in lymphoma tissue. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/hon.2562DOI Listing
September 2018
2 Reads

The role of maintenance therapy in patients with diffuse large B cell lymphoma: A systematic review and meta-analysis.

Hematol Oncol 2019 Feb 8;37(1):27-34. Epub 2018 Oct 8.

Institute of Hematology, Davidoff Cancer Center, Rabin Medical Center, Petah Tikva, Israel.

Randomized trials of maintenance therapy (MT) in diffuse large B cell lymphoma (DLBCL) are inconclusive regarding its effect on overall survival (OS) and disease control. We aimed to examine the efficacy and safety of MT in this meta-analysis. Systematic review and meta-analysis of randomized controlled trials comparing MT with observation or placebo, in patients with DLBCL, who achieved complete response (CR) or partial response (PR) after first-line chemotherapy with or without rituximab. Read More

View Article

Download full-text PDF

Source
http://doi.wiley.com/10.1002/hon.2561
Publisher Site
http://dx.doi.org/10.1002/hon.2561DOI Listing
February 2019
21 Reads

Outcome of patients with relapsed or refractory anaplastic large cell lymphoma who have failed brentuximab vedotin.

Hematol Oncol 2019 Feb 23;37(1):35-38. Epub 2018 Oct 23.

Department of Lymphoma/Myeloma, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.

Brentuximab vedotin (BV) is an anti-CD30 antibody-drug conjugate that is highly effective in patients with relapsed/refractory anaplastic large cell lymphoma (ALCL). However, survival outcomes following suboptimal response or subsequent relapse are not well known. We conducted a multicenter study analyzing outcomes of patients with relapsed/refractory ALCL who have received BV with a secondary focus on survival after progression following BV. Read More

View Article

Download full-text PDF

Source
http://doi.wiley.com/10.1002/hon.2560
Publisher Site
http://dx.doi.org/10.1002/hon.2560DOI Listing
February 2019
15 Reads

Diagnostic framing of IgM monoclonal gammopathy: Focus on Waldenström macroglobulinemia.

Hematol Oncol 2018 Sep 7. Epub 2018 Sep 7.

Division of Hematology, Fondazione IRCCS Policlinico S. Matteo, Pavia, Italy.

The finding of an IgM monoclonal gammopathy often represents a diagnostic challenge. In fact, there are many pathological disorders associated with this condition, each of which has distinctive characteristics and requires specific clinical, instrumental, and laboratory assessments to set the appropriate treatment. This review has two aims. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/hon.2539DOI Listing
September 2018
9 Reads

Management of adverse events associated with idelalisib treatment in chronic lymphocytic leukemia and follicular lymphoma: A multidisciplinary position paper.

Hematol Oncol 2019 Feb 5;37(1):3-14. Epub 2018 Sep 5.

Institute of Hematology Lorenzo e Ariosto Seràgnoli, University of Bologna, Bologna, Italy.

The introduction of new therapeutic agents in chronic lymphocytic leukemia (CLL) and follicular lymphoma (FL), including the new kinase inhibitor idelalisib, has changed the therapeutic landscape of these diseases. However, the use of idelalisib is associated with a peculiar profile of side effects, which require an optimization of the current approach to prophylaxis and supportive treatment. Moving from the recognition that the abovementioned issue represents an unmet need in CLL and FL, a multidisciplinary panel of experts was convened to produce a consensus document aiming to provide practical recommendations for the management of the side effects during idelalisib therapy for CLL and FL. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/hon.2540DOI Listing
February 2019
4 Reads

Unsuppressed serum albumin levels may jeopardize the clinical relevance of the international staging system to patients with light chain myeloma.

Hematol Oncol 2018 Dec 19;36(5):792-800. Epub 2018 Sep 19.

Department of Hematology/Oncology, Higashi Nagoya National Hospital, Nagoya, Japan.

The international staging system (ISS) is the most commonly used risk-stratification system for patients with multiple myeloma (MM) and is determined by serum albumin and β2-microglobulin levels. In the two determinants, β2-microglobulin levels are frequently observed to be elevated in patients with myeloma, particularly in those with renal impairment. In comparison with patients with intact immunoglobulin myeloma, patients with LC myeloma do not necessarily show decreased levels of serum albumin. Read More

View Article

Download full-text PDF

Source
http://doi.wiley.com/10.1002/hon.2559
Publisher Site
http://dx.doi.org/10.1002/hon.2559DOI Listing
December 2018
15 Reads

The outcome and characteristics of patients with relapsed adult T cell leukemia/lymphoma after allogeneic hematopoietic stem cell transplantation.

Hematol Oncol 2019 Feb 28;37(1):54-61. Epub 2018 Sep 28.

Department of Hematology, Imamura General Hospital, Kagoshima, Japan.

Treatment options for patients with adult T cell leukemia/lymphoma (ATLL) who have relapsed disease after allogeneic hematopoietic stem cell transplantation (allo-HSCT) are limited. To clarify which patients with ATLL are likely to benefit from these treatment options and to define patient populations for novel treatments, we performed a nationwide retrospective analysis of 252 Japanese patients who had relapsed ATLL after allo-HSCT. Some long-term survivors remained after tapering and withdrawal of immunosuppressive agents. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/hon.2558DOI Listing
February 2019
2 Reads

Safety and tolerability of lurbinectedin (PM01183) in patients with acute myeloid leukemia and myelodysplastic syndrome.

Hematol Oncol 2019 Feb 5;37(1):96-102. Epub 2018 Dec 5.

Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.

Trabectedin is an FDA-approved DNA minor groove binder that has activity against translocation-associated sarcomas. Lurbinectedin is a next-generation minor groove binder with preclinical activity against myeloid leukemia cells. A dose-finding phase 1 clinical trial was performed in patients with acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS) with further assessment of safety and tolerability. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/hon.2557DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6386594PMC
February 2019
15 Reads

Treatment of mucosa associated lymphoid tissue lymphoma with a long-term once-weekly regimen of oral azithromycin: Results from the phase II MALT-A trial.

Hematol Oncol 2019 Feb 19;37(1):22-26. Epub 2018 Sep 19.

Department of Medicine 1, Division of Oncology, Medical University of Vienna, Vienna, Austria.

The macrolide clarithromycin has been reported as active for therapy of mucosa associated lymphoid tissue (MALT) lymphoma. Pharmacokinetic properties, however, require continuous daily intake over a prolonged period of time. As the macrolide azithromycin is characterized by a long half-life as well as potential antineoplastic activity in vitro, we have performed a phase II trial of long-term once-weekly oral azithromycin for treatment of MALT lymphoma. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/hon.2555DOI Listing
February 2019
8 Reads

Renewed interest for low-dose radiation therapy in follicular lymphomas: From biology to clinical applications.

Hematol Oncol 2018 Dec 26;36(5):723-732. Epub 2018 Aug 26.

Radiation Oncology Unit, Fondazione IRCCS Policlinico S. Matteo, Pavia, Italy.

Follicular lymphoma (FL) is the most common subtype of indolent non-Hodgkin lymphoproliferative disorders. Treatment strategies for FL may include several therapeutic choices, ranging from a "watchful waiting" approach to stem cell transplantation, mostly depending on staging, age, risk factors, and disease burden at diagnosis. The high radiosensitivity of FL compared with other solid tumors has been known since the beginning of radiotherapy treatment in lymphoma patients. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/hon.2538DOI Listing
December 2018
8 Reads